Valuation: Exelixis, Inc.

Capitalization 12.6B 10.83B 9.91B 9.41B 17.32B 1,214B 17.62B 119B 45.95B 574B 47.29B 46.29B 2,002B P/E ratio 2026 *
15.9x
P/E ratio 2027 * 13.5x
Enterprise value 11.83B 10.16B 9.3B 8.83B 16.26B 1,140B 16.54B 111B 43.14B 539B 44.4B 43.46B 1,880B EV / Sales 2026 *
4.56x
EV / Sales 2027 * 3.73x
Free-Float
98.04%
Yield 2026 *
-
Yield 2027 * -
1 day-0.46%
1 week+0.73%
Current month+12.63%
1 month+14.82%
3 months+12.60%
6 months+17.41%
Current year+14.25%
1 week 48.82
Extreme 48.82
51.63
1 month 43.5
Extreme 43.5
51.63
Current year 39.71
Extreme 39.71
51.63
1 year 33.76
Extreme 33.755
51.63
3 years 18.64
Extreme 18.64
51.63
5 years 14.87
Extreme 14.87
51.63
10 years 5.26
Extreme 5.255
51.63
Manager TitleAgeSince
Chief Executive Officer 65 21/07/2010
Director of Finance/CFO 58 14/07/2015
Chief Operating Officer 63 31/01/2016
Director TitleAgeSince
Director/Board Member 69 31/01/2004
Director/Board Member 82 31/07/2004
Chairman 77 31/12/1997
Change 5d. change 1-year change 3-years change Capi.($)
-0.40%+0.73%+12.05%+153.80% 12.6B
-2.54%-2.26%+33.25%+75.07% 50.1B
-1.05%-4.45%+66.31%+50.52% 45.82B
-2.46%+1.60%+55.49%+460.84% 23.66B
-1.85%-5.66%-9.96%-16.10% 22.65B
-2.20%+0.86%+39.87%-26.56% 17.8B
+0.39%+1.90%+28.07%-41.95% 16.08B
-5.32%-15.07%+36.29%+202.26% 14.14B
-6.64%-15.43%-34.28%+874.07% 13.09B
-2.84%-5.14%+32.07% - 13B
Average -2.52%-1.83%+25.92%+192.44% 22.89B
Weighted average by Cap. -2.27%-1.48%+33.13%+146.85%

Financials

2026 *2027 *
Net sales 2.59B 2.23B 2.04B 1.94B 3.57B 250B 3.63B 24.41B 9.46B 118B 9.74B 9.53B 412B 2.92B 2.51B 2.29B 2.18B 4.01B 281B 4.08B 27.45B 10.64B 133B 10.95B 10.72B 463B
Net income 816M 701M 642M 609M 1.12B 78.64B 1.14B 7.68B 2.98B 37.21B 3.06B 3B 130B 947M 814M 745M 707M 1.3B 91.25B 1.32B 8.91B 3.45B 43.17B 3.55B 3.48B 150B
Net Debt -770M -662M -605M -575M -1.06B -74.18B -1.08B -7.25B -2.81B -35.1B -2.89B -2.83B -122B -1.73B -1.49B -1.36B -1.29B -2.38B -167B -2.42B -16.29B -6.31B -78.9B -6.5B -6.36B -275B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
18/05/26 50.00 $ -0.25% 1,185,990
15/05/26 50.13 $ -1.90% 2,069,205
14/05/26 51.10 $ -0.37% 2,420,763
13/05/26 51.29 $ +3.70% 3,241,148
12/05/26 49.46 $ -0.50% 2,766,765
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
50.13USD
Average target price
49.06USD
Spread / Average Target
-2.14%

Quarterly revenue - Rate of surprise